Relative contraindications may include significant cancer risk factors, bleeding disorders, and concurrent use of anticoagulant medications
Different patients have different comorbidities, GI tolerance, exercise limitations, nutritional risk, and treatment goals
Brain Res Prot 7 : 1120
Walter, M., Philotheou, A., Bonnici, F., Ziegler, A.-G
Protects against environmental damage and free radicals
CJC-1295 No DAC : Ipamorelin : CJC-1295 No DAC & Ipamorelin CERTIFICATES OF ANALYSIS 5 COAs BN-25CI55-003 Current Variant: Size: 5mg-5mg CJC-1295 5.18 mg / 4.92 mg Ipamorelin 5.22 mg / 4.96 mg BN-25CI55 Upcoming Variant: Size: 5mg-5mg CJC-1295 4.95 mg Ipamorelin 5.35 mg BN-25CI55-002 Previous Variant: Size: 5mg-5mg BN-25CI55-001 Previous Variant: Size: 5mg-5mg BN-25CI55-001 Previous Variant: Size: 5mg-5mg Small-Batch Research Confidence Focused research supply, documented batch by batch